Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trialBrian G. Feagan, Laurent Peyrin‐Biroulet, Ronald Fogel et al.|The Lancet|2021Cited by 452
A Phase 2, Randomized, Placebo-Controlled Study Evaluating Matrix Metalloproteinase-9 Inhibitor, Andecaliximab, in Patients With Moderately to Severely Active Crohn’s DiseaseStefan Schreiber, Edward V. Loftus, Corey A. Siegel et al.|Journal of Crohn s and Colitis|2018Cited by 51
A15 EFFICACY AND SAFETY OF FILGOTINIB AS INDUCTION THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDYB G Feagan, Laurent Peyrin‐Biroulet, Edward V. Loftus et al.|Journal of the Canadian Association of Gastroenterology|2021Cited by 8